Abstract:Abstract Alopecia areata (AA) is an autoimmune-mediated, nonscarring hair loss that affects 2% of the population. Patients with AA experience significant impairment in health-related quality of life (HRQoL), particularly mental health (Senna M, Ko J, Glashofer M et al. Predictors of QOL in patients with alopecia areata. J Invest Dermatol 2022; 142: 2646–50). The Severity of Alopecia Tool (SALT) is a physician-derived, semiobjective measure, frequently used in clinical practice, that calculates the extent of scalp hair loss. Nonscalp hair or quality of life is not incorporated and may explain why SALT can underestimate the overall impact of AA (Senna et al.; Wall D, Rees H, Bokhari L et al. Signposts to the promised land in alopecia areata. J Invest Dermatol 2023; 143: 9–10). The Dermatology Life Quality Index (DLQI) and Hospital Anxiety and Depression Scale (HADS) are common HRQoL assessments. Emerging disease-specific tools, which examine both hair loss extent and quality-of-life impact, include the Alopecia Areata Patient Priority Outcomes (AAPPO) and the Alopecia Areata Symptom Impact Scale (AASIS). This study aimed to determine the baseline HRQoL burden among adult patients with AA in a newly developed hair research clinic. A secondary aim was to examine how HRQoL assessments compared with SALT vs. newer compound measures, AAPPO and AASIS. A retrospective chart review identified 20 patients with complete data. The mean SALT score was 61.2. The mean DLQI score was 11.05, indicating a very large impact on QoL as measured by DLQI bands. Overall, 15% of patients experienced no effect, 25% a small effect, 10% a moderate effect, 30% a very large effect and 20% an extremely large effect. The mean HADS-D (depression) score was 8, indicating a borderline score. In total, 47% had normal scores, 21% had borderline scores and 32% had abnormal scores. Similarly, the mean HADS-A (anxiety) score was borderline at 9.9; 26% had normal scores, 21% borderline scores and 53% abnormal scores. The mean total AAPPO score was 16.8 out of 44. The highest mean subscore was the emotional symptoms subscore of 9.9 out of 16, followed by a hair loss subscore of 9 out of 16 and an activity limitations subscore of 3.9 out of 12. The mean total AASIS score was 118 out of 170. The highest mean subscore was the symptoms subscore of 36.9 out of 70, followed by the feelings subscore of 17.5 out of 40 and daily functioning subscore of 24.1 out of 60. SALT had a nonsignificant positive association with HRQoL. AAPPO and AASIS had significant positive associations with HRQoL. In conclusion, our study has demonstrated a significant impact on HRQoL among patients with AA, irrespectively of the degree of hair loss. Our study has also shown that the emerging disease-specific tools, AAPPO and AASIS, are superior in determining the overall impact of AA compared with SALT.

Comparing quality of life, anxiety, depression, sleep disturbance, and associated factors in vitiligo and alopecia areata patients

Alopecia Areata-Quality of Life Index questionnaire (reliability and validity of the Persian version) in comparison to Dermatology Life Quality Index

BH08 Evaluating quality-of-life measures for alopecia: a comparative analysis of Dermatology Life Quality Index and Hospital Anxiety and Depression Scale correlations with disease severity

The Relationship Between Patient-Reported Severity of Hair Loss and Health-Related Quality of Life and Treatment Patterns Among Patients with Alopecia Areata

Psychosocial and mental impact of alopecia areata: Analysis of the Danish Skin Cohort

Assessing a measure for Quality of Life in patients with severe Alopecia Areata: a multicentric Italian study

BH15 The burden of alopecia areata: examining baseline health-related quality of life and clinical assessment tools

Sleep Quality and Related Factors in 136 Cases of Alopecia Areata

Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature Review

Anxiety and depression in pediatric patients with vitiligo and alopecia areata and their parents: A cross-sectional controlled study

Physician- and Patient-Reported Severity and Quality of Life Impact of Alopecia Areata: Results from a Real-World Survey in Five European Countries

Evaluating prevalence of depression, anxiety and hopelessness in patients with Vitiligo on an Iranian population

Evaluation of quality of life scores and family impact scales in pediatric patients with alopecia areata: a cross‐sectional cohort study

0918 A Cross-sectional Study on the Cytokine Profiles and Immunological Relationship Between Vitiligo and Sleep Quality

Assessment of the Quality of Life of Vitiligo Patients: A Cross-Sectional Study in the Eastern Region of Saudi Arabia

Validation of the DLQI questionnaire in assessing the disease burden and principal aspects related to life quality of vitiligo patients

Serum brain-derived neurotrophic factor and vitamin D: Two concordant players controlling depression among alopecia areata and vitiligo patients: A case-control study

Psychometric Properties of the EQ-5D-5L in Patients with Alopecia Areata

Comparison of quality of life, depression and fatigue in patients with psoriasis and psoriatic arthritis

Health‐related quality of life of adult and adolescent patients living with alopecia areata in Australia